Benitec Biopharma Reports Promising Interim Results For BB-301 Gene Therapy In OPMD Trial
(RTTNews) - Benitec Biopharma Inc. (BNTC) on Monday, announced encouraging interim results from its Phase 1b/2a clinical study evaluating BB-301, a gene therapy for Oculopharyngeal Muscular Dystrophy...
Nasdaq News: Markets·8d ago